Invizyne Technologies Inc. Files S-1/A Amendment

TL;DR

Invizyne IPO update: S-1/A filed 9/6. Looks like they're still aiming to go public.

AI Summary

Invizyne Technologies Inc. filed an S-1/A amendment on September 6, 2024, for its initial public offering. The company, incorporated in Nevada, is seeking to register an unspecified number of shares. Its principal executive offices are located at 750 Royal Oaks Drive, Monrovia, CA 91016, with a business phone number of (626) 415-1488.

Why It Matters

This filing indicates Invizyne Technologies Inc. is moving forward with its public offering, which could provide the company with capital for growth and expansion.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to go public, which inherently carries risks associated with market reception and operational execution.

Key Numbers

• 20240906 — Filing Date (Date of the S-1/A amendment filing.)
• 2836 — SIC Code (Standard Industrial Classification for Biological Products.)

Key Players & Entities

• Invizyne Technologies Inc. (company) — Registrant
• Michael Heltzen (person) — Chief Executive Officer
• Andrew Hudders (person) — Legal Counsel
• Aaron A. Grunfeld (person) — Legal Counsel
• 750 Royal Oaks Drive, Monrovia, CA 91016 (location) — Principal Executive Offices
• 333-276987 (registration_number) — SEC File Number

FAQ

Key Financial Figures

• $0.000001 — 0 shares of its common stock, par value $0.000001 (“Common Stock”), coupled w
• $4.00 — s being offered at a price per share of $4.00. The public offering price was determin
• $200,000 — its accountable expenses, not to exceed $200,000. We will pay the qualified independent
• $100,000 — lified independent underwriter a fee of $100,000, of which $25,000 has been paid in adva
• $25,000 — underwriter a fee of $100,000, of which $25,000 has been paid in advance. The registrat
• $5.00 — e underwriters, at an exercise price of $5.00 (125% of the public offering price). Se
• $1,380,000 — scounts and commissions payable will be $1,380,000 and the total proceeds net of discounts
• $17,250,000 — ssions, to us, before expenses, will be $17,250,000. The underwriter expects to deliver t

Filing Documents

• forms-1a.htm (S-1/A) — 2028KB
• ex5-1.htm (EX-5.1) — 15KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107-1.htm (EX-FILING FEES) — 25KB
• forms-1a_002.jpg (GRAPHIC) — 15KB
• forms-1a_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-035313.txt ( ) — 2101KB

Use of Proceeds

Use of Proceeds 25 Dividend Policy 25 Capitalization 25

Dilution

Dilution 26 Management’s Discussion and Analysis of Financial Condition and Results of Operations 27

Business

Business 35 Management 47

Executive Compensation

Executive Compensation 53 Certain Relationships and Related Party Transactions 55 Principal Shareholders 55 Description of Capital 56

Underwriting

Underwriting (Conflicts of Interest) 59 Sales of Restricted Securities and Rule 144 63 Legal Matters 64 Experts 64 Additional Information 64 Index to Consolidated Financial Statements F-1 Neither we nor the underwriter have authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the underwriter take any responsibility for, and can provide no assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus, and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of the shares of Common Stock means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy the shares of Common Stock in any circumstances under which such offer or solicitation is unlawful. You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriter have authorized anyone to provide you with information that is different. We and the underwriter are offering to sell the shares of Common Stock, and seeking offers to buy the shares of Common Stock, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of Common Stock. For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the

View Full Filing

View this S-1/A filing on SEC EDGAR